NCT04871737View on ClinicalTrials.gov

Study of a Live rNDV Based Vaccine Against COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

August 21, 2022

Study Completion Date

September 30, 2022

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Recombinant NDV Vectored Vaccine for SARS-CoV-2

Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Trial Locations (1)

Unknown

Hospital Medica Sur, Mexico City

All Listed Sponsors
collaborator

National Council of Science and Technology, Mexico

OTHER

collaborator

Agencia Mexicana de Cooperación Internacional para el Desarrollo. AMEXCID

UNKNOWN

lead

Laboratorio Avi-Mex, S.A. de C.V.

INDUSTRY